Daxiang Biotech participated in the 2026 International MPS Society Asia-Pacific Summit & 9th Organoid and Organ-on-a-Chip Conference, held in Nanjing from September 21–24, 2026.

Daxiang Biotech has joined Scientist.com as a Registered Supplier, creating a new way for pharmaceutical, biotech, and research organizations worldwide to access its organoid, organoid-on-chip, and microphysiological system (MPS) technologies and research services.

Daxiang Biotech has been awarded Second Prize in the Finals of the HICOOL 2026 Global Entrepreneurship Competition, recognizing the company's innovation and commercialization efforts in organoid-on-chip technology.

Daxiang Biotech joined the 14th Tumor Models Summit Boston, held July 29–30, 2026, alongside researchers and industry leaders working to advance more predictive and translationally relevant models for oncology drug development.

Daxiang Biotech has been recognized as the “Top Organoids-on-Chips Model Services in Asia 2026” by Life Sciences Review, highlighting the company’s innovation and contributions to advancing organoid-on-chip technologies for biomedical research, drug discovery, and preclinical development.

Daxiang Biotech introduces Oakuloid™ ToxPredictor, an AI-enabled organoid-on-chip platform designed to support early toxicity prediction and human-relevant safety assessment.

Mr. Yu Zhou, Founder & CEO of Daxiang Biotech, led the company's international team in presenting Daxiang's proprietary technologies to pharmaceutical companies, biotechnology innovators, CROs, research institutions, and investors from around the world.

Daxiang Biotech joined global leaders in Microphysiological Systems (MPS) research and innovation at MPS World Summit 2026, where the company showcased its integrated Organoids-on-Chips platform and engaged with researchers, industry partners, and innovators from around the world.

Daxiang Biotech utilized the IBAC O2 chip to construct a tumor organoid immune co-culture model. This model effectively recreated the immune microenvironment of human tumors and evaluated the efficacy of QLF3108.

Humanized and highly advanced organoids on chips models have emerged as a crucial technology platform for evaluating cell therapy drugs and conducting translational medicine research. Data of organoids on chips facilitate clinical approval of CAR-T drugs for solid tumors.